(Q38921198)

7 September 2017

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials (English)

1 reference

7 September 2017

0 references

1 reference

6

Jeannie Visootsak

1 reference

7 September 2017

2

Vincent Des Portes

1 reference

7 September 2017

Elizabeth Berry-Kravis

1

1 reference

7 September 2017

Randi Hagerman

3

1 reference

7 September 2017

Sébastien Jacquemont

4

1 reference

7 September 2017

Perrine Charles

5

1 reference

7 September 2017

Marc Brinkman

7

1 reference

7 September 2017

Karin Rerat

8

1 reference

7 September 2017

Barbara Koumaras

9

1 reference

7 September 2017

Liansheng Zhu

10

1 reference

7 September 2017

Gottfried Maria Barth

11

1 reference

7 September 2017

Thomas Jaecklin

12

1 reference

7 September 2017

George Apostol

13

1 reference

7 September 2017

Florian von Raison

14

1 reference

7 September 2017

language of work or name

English

0 references

publication date

1 January 2016

1 reference

Science Translational Medicine

7 September 2017

1 reference

7 September 2017

8

1 reference

7 September 2017

321

1 reference

7 September 2017

321ra5

1 reference

Autism spectrum disorders: the quest for genetic syndromes

7 September 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Exploring the adult life of men and women with fragile X syndrome: results from a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

The FMRP regulon: from targets to disease convergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Altered synaptic plasticity in a mouse model of fragile X mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

The trouble with spines in fragile X syndrome: density, maturity and plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

The mGluR theory of fragile X mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

The translation of translational control by FMRP: therapeutic targets for FXS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

The Repetitive Behavior Scale-Revised: Independent Validation in Individuals with Autism Spectrum Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4109

10.1126/SCITRANSLMED.AAB4109

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference